Table 2.

League Table of Random-Effects Network Meta-Analysis for Effect of Urate-Lowering Therapy*

Serum Uric Acid Level (Short-Term Follow-Up, mg/dL)
Allopurinol..−2.16 (−3.20 to −1.13)
0.89 (−1.49 to 3.26)Benzbromarone.−3.05 (−5.19 to −0.91)
0.55 (−1.03 to 2.13)−0.34 (−2.79 to 2.11)Febuxostat−2.71 (−3.90 to −1.52)
−2.16 (−3.20 to −1.13)−3.05* (−5.19 to −0.91)−2.71 (−3.90 to −1.52)Placebo
Serum Uric Acid Level (Long-Term Follow-Up, mg/dL)
Allopurinol.−3.17 (−5.19 to −1.15)
−0.55 (−3.97 to 2.88)Febuxostat−2.62 (−5.39 to 0.15)
−3.17 (−5.19 to −1.15)−2.62 (−5.39 to 0.15)Placebo
Renal Function (Short-Term Follow-Up, mL/min/1.73 m2)
Allopurinol.3.07 (0.18 to 5.95)
2.00 (−2.54 to 6.53)Febuxostat1.07 (−2.43 to 4.57)
3.07 (0.18 to 5.95)1.07 (−2.43 to 4.57)Placebo
Renal Function (Long-Term Follow-Up, mL/min/1.73 m2)
Allopurinol.4.10 (2.66 to 5.54)
3.70 (1.94 to 5.46)Febuxostat0.40 (−0.60 to 1.40)
4.10 (2.66 to 5.54)0.40 (−0.60 to 1.40)Placebo
Systolic Blood Pressure (Short-Term Follow-Up, mm Hg)
Allopurinol.0.04 (−4.22 to 4.30)
4.54 (−4.29 to 13.37)Febuxostat−4.50 (−12.23 to 3.23)
0.04 (−4.22 to 4.30)−4.50 (−12.23 to 3.23)Placebo
Systolic Blood Pressure (Long-Term Follow-Up, mm Hg)
Allopurinol.−4.74 (−11.12 to 1.63)
−3.96 (−10.58 to 2.66)Febuxostat−0.78 (−2.57 to 1.01)
−4.74 (−11.12 to 1.63)−0.78 (−2.57 to 1.01)Placebo
Diastolic Blood Pressure (Short-Term Follow-Up, mm Hg)
Allopurinol.1.58 (−2.31 to 5.48)
1.48 (−4.06 to 7.03)Febuxostat0.10 (−3.85 to 4.05)
1.58 (−2.31 to 5.48)0.10 (−3.85 to 4.05)Placebo
Diastolic Blood Pressure (Long-Term Follow-Up, mm Hg)
Allopurinol.0.86 (−3.88 to 5.61)
2.34 (−2.62 to 7.29)Febuxostat−1.47 (−2.90 to −0.04)
0.86 (−3.88 to 5.61)−1.47 (−2.91 to −0.04)Placebo
  • * Data are shown as mean difference (95% confidence interval).

  • Difference in treatment effect is statistically significant.